Chikungunya Pipeline Insight 2025: 10+ Advancing Therapies and Key Companies in the Chikungunya Treatment Landscape | DelveInsight

The therapeutic landscape for Chikungunya, a viral disease transmitted by mosquitoes that causes severe joint pain, fever, and rash, is rapidly evolving, fueled by advancements in antiviral research and vaccine development. Leading biopharmaceutical companies such as Valneva, Moderna Therapeutics, Themis Bioscience, FIT Biotech, Bharat Biotech, and Emergex Vaccines are at the forefront of developing innovative therapies, targeting various stages of the virus lifecycle, immune modulation, and pain management to alleviate symptoms and potentially halt disease progression.

DelveInsight's Chikungunya - Pipeline Insight, 2025 offers a comprehensive evaluation of the clinical and preclinical pipeline, providing detailed insights into emerging drug candidates, their mechanisms of action, trial progress, and expected regulatory timelines. The report highlights investigational therapies, ranging from novel antivirals to immune modulators and vaccines, that aim to reduce viral load, alleviate pain, and prevent long-term joint damage.

Additionally, this pipeline assessment provides a 360° view of drug development by analyzing trends across clinical phases, therapeutic classes, administration routes, and global trial geographies. The report also examines key unmet needs in chikungunya treatment, strategic partnerships, regulatory designations, and innovations that are anticipated to reshape the future of chikungunya management and therapeutic interventions.

Interested in learning more about the current treatment landscape and the key drivers shaping the chikungunya pipeline? Click here: https://www.delveinsight.com/report-store/chikungunya-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Chikungunya Pipeline Report
• DelveInsight's chikungunya pipeline analysis depicts a strong space with 10+ active players working to develop 10+ pipeline drugs for chikungunya treatment.
• The leading chikungunya companies include Valneva, Moderna Therapeutics, Themis Bioscience, FIT Biotech, Bharat Biotech, Emergex Vaccines, Emergent BioSolutions, Indian Immunologicals Ltd., Auro Vaccines, Riboscience, and others are evaluating their lead assets to improve the chikungunya treatment landscape.
• Key chikungunya pipeline therapies in various stages of development include VLA1553, Molnupiravir, MV-CHIK, BBV 87, VRC CHKVLP059 00 VP, Research programme: neglected tropical diseases therapeutics, and others.
• In May 2025, the FDA and EU flagged safety concerns with Valneva's chikungunya vaccine, IXCHIQ, after identifying serious neurologic and cardiac events in older adults. Both the FDA and CDC have recommended pausing its use in seniors 60 years and older while safety investigations continue.
• In February 2025, Bavarian Nordic A/S announced that the U.S. FDA approved VIMKUNYATM (Chikungunya Vaccine, Recombinant), the first single-dose, virus-like particle chikungunya vaccine for individuals aged 12 and older.
• In November 2023 of FDA approval for IXCHIQ, which became the world's first approved chikungunya vaccine. Ixchiq is a single-dose, live-attenuated vaccine aimed at preventing chikungunya virus (CHIKV) infection in adults aged 18 and older. It was expected to mitigate a significant public health risk and prevent millions of chikungunya cases globally.

Request a sample and discover the recent breakthroughs happening in the chikungunya pipeline landscape @ https://www.delveinsight.com/report-store/chikungunya-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chikungunya Overview
Chikungunya is a viral infection transmitted to humans through mosquito bites carrying the chikungunya virus. First identified during an outbreak in southern Tanzania in 1952, it has since spread to nearly 40 countries across Asia, Africa, Europe, and the Americas. Symptoms typically develop 4 to 8 days after infection, though they can appear anywhere from 2 to 12 days. The primary symptom is a sudden onset of fever, often accompanied by joint pain. Additional symptoms include muscle pain, headache, nausea, fatigue, and a rash. While severe joint pain usually lasts a few days, it can persist for months or even years. Although serious complications are rare, severe cases can lead to long-term symptoms and, in extreme instances, death, particularly in older adults.

Find out more about chikungunya medication @ https://www.delveinsight.com/report-store/chikungunya-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chikungunya Treatment Analysis: Drug Profile
VLA1553: Valneva
VLA1553 is a chikungunya vaccine candidate currently in Phase III clinical trials, designed to provide long-term protection with a single dose. In August 2021, Valneva announced positive topline results from a pivotal Phase 3 trial involving 4,115 adults aged 18 and older across 44 U.S. sites. The trial successfully met its primary endpoint, inducing protective CHIKV-neutralizing antibody titers in 98.5% of participants 28 days after a single dose. The vaccine was generally well tolerated by the 3,082 subjects who were evaluated for safety. VLA1553 has been granted Fast Track and Breakthrough Therapy designations by the FDA and PRIME designation by the EMA.

Learn more about the novel and emerging chikungunya pipeline therapies @ https://www.delveinsight.com/report-store/chikungunya-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chikungunya Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Chikungunya Pipeline Report
• Coverage: Global
• Key Chikungunya Companies: Valneva, Moderna Therapeutics, Themis Bioscience, FIT Biotech, Bharat Biotech, Emergex Vaccines, Emergent BioSolutions, Indian Immunologicals Ltd., Auro Vaccines, Riboscience, and others.
• Key Chikungunya Pipeline Therapies: VLA1553, Molnupiravir, MV-CHIK, BBV 87, VRC CHKVLP059 00 VP, Research programme: neglected tropical diseases therapeutics, and others.

Dive deep into rich insights for drugs used for chikungunya treatment; visit @ https://www.delveinsight.com/report-store/chikungunya-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Chikungunya Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chikungunya Pipeline Therapeutics
6. Chikungunya Pipeline: Late-Stage Products (Phase III)
7. Chikungunya Pipeline: Mid-Stage Products (Phase II)
8. Chikungunya Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.